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Introduction: Patients with rheumatoid arthritis (RA) can be separated into two major subpopulations based on
the absence or presence of serum anti-citrullinated protein antibodies (ACPAs). The more severe disease course in
ACPA+ RA and differences in treatment outcome between these subpopulations suggest that ACPA+ and ACPA−
RA are different disease subsets. The identification of T-helper (Th) cells specifically recognizing citrullinated peptides,
combined with the strong association between HLA-DRB1 and ACPA positivity, point toward a pathogenic role of Th
cells in ACPA+ RA. In this context we recently identified a potential pathogenic role for CCR6+ Th cells in RA. Therefore,
we examined whether Th cell population distributions differ by ACPA status.
Methods: We performed a nested matched case–control study including 27 ACPA+ and 27 ACPA− treatment-naive
early RA patients matched for disease activity score in 44 joints, presence of rheumatoid factor, sex, age, duration of
complaints and presence of erosions. CD4+CD45RO+ (memory) Th cell distribution profiles from these patients were
generated based on differential chemokine receptor expression and related with disease duration.
Results: ACPA status was not related to differences in total CD4+ T cell or memory Th cell proportions. However,
ACPA+ patients had significantly higher proportions of Th cells expressing the chemokine receptors CCR6 and
CXCR3. Similar proportions of CCR4+ and CCR10+ Th cells were found. Within the CCR6+ cell population, four Th
subpopulations were distinguished based on differential chemokine receptor expression: Th17 (CCR4+CCR10−),
Th17.1 (CXCR3+), Th22 (CCR4+CCR10+) and CCR4/CXCR3 double-positive (DP) cells. In particular, higher proportions of
Th22 (p = 0.02), Th17.1 (p = 0.03) and CCR4/CXCR3 DP (p = 0.01) cells were present in ACPA+ patients. In contrast, ACPA
status was not associated with differences in Th1 (CCR6−CXCR3+; p = 0.90), Th2 (CCR6−CCR4+; p = 0.27) and T-regulatory
(CD25hiFOXP3+; p = 0.06) cell proportions. Interestingly, CCR6+ Th cells were inversely correlated with disease duration in
ACPA− patients (R2 = −0.35; p < 0.01) but not in ACPA+ (R2 < 0.01; p = 0.94) patients.
Conclusions: These findings demonstrate that increased peripheral blood CCR6+ Th cells proportions distinguish
ACPA+ RA from ACPA− RA. This suggests that CCR6+ Th cells are involved in the differences in disease severity
and treatment outcome between ACPA+ and ACPA− RA.
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Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic synovial joint inflammation and
auto-antibody presence [1, 2]. The presence of serum
anti-citrullinated protein antibodies (ACPAs) is highly
specific for RA, and ~70 % of patients with RA are
ACPA+ [3–5]. Moreover, ACPAs are a useful marker for
RA diagnosis as they can be present several years before
clinical onset [6, 7].
The disease course in ACPA+ patients is worse than in
ACPA− patients, as shown, for example, from more devel-
opment of erosions; and treatment outcomes differ between
these groups [8–17]. Moreover, associations between the
HLA-DRB1 shared epitope (SE) alleles, PTPN22 gene
polymorphisms and smoking have been found in ACPA+
patients [4, 18–21].
The association between HLA-DRB1 SE and ACPA positiv-
ity implicates a role for MHC class II-dependent CD4+ T cell
activation in ACPA+ RA [22]. In line with this, ACPAs are of
the IgG subtype, which indicates that ACPA-producing B
cells have undergone T cell-dependent class switching
[23]. Moreover, citrullinated epitope specific T cells have
been identified in ACPA+ patients [24–26].
CD4+ T helper (Th) cells and their cytokines play a
central role in RA pathogenesis [27]. In early RA, pro-
inflammatory T cells migrate to inflammatory sites and
contribute to disease progression [27–29]. Cytokines
produced by T cells, such as TNFα and IL-17A, are in-
volved in activation of local cells and in inflammatory
cell recruitment [29–31].
Th cell populations are characterized by differential
chemokine receptor expression. For instance, IFNγ produ-
cing Th1 cells are CCR6−CXCR3+CCR4−, and IL-4 produ-
cing Th2 cells are CCR6−CXCR3−CCR4+ [32]. IL-17A and
IL-22 producing cells are primarily found in the heteroge-
neous CCR6+ T cell population, with its subpopulations
based on CXCR3, CCR4 and CCR10 expression. CCR6+
cells with Th17 characteristics are CXCR3−CCR4+CCR10−
and CCR6+ cells with Th22 characteristics are CXCR3−
CCR4+CCR10+ [33–35]. CCR6+CXCR3+CCR4− T cells
exhibit both Th17 and Th1 features and are named non-
classic Th1 or Th17.1 cells [36–38].
Recently we identified a potential role for CCR6+ Th
cells in the pathogenesis of RA. In particular CCR6+ Th
cells and not CCR6− Th cells were potent inducers of
synovial fibroblast activation. This resulted in a pro-
inflammatory feedback loop leading to the induction of
pro-inflammatory mediators, such as IL-1β, IL-6 and PGE2
and the tissue degrading enzymes MMP-1 and MMP-3.
This loop was dependent on TNFα and IL-17A and may
play an important role in the progression of an early in-
flammation towards a chronic persistent arthritis [30, 31].
The strong indications of T cell involvement in ACPA+
RA, and the clinical and molecular differences betweenACPA+ and ACPA− disease, prompted us to investigate
differences in Th cell populations between ACPA+ and
ACPA− RA patients. In this report we describe that
ACPA+ patients differ from ACPA− patients by significantly
higher memory CCR6+ Th cell proportions. These findings
suggest that pathogenic memory CCR6+ Th cells may be
involved in the worse disease course observed in ACPA+
RA patients.
Methods
Patients
We performed a nested matched case–control study in-
cluding 27 ACPA+ and 27 ACPA− treatment-naive early
RA patients matched for disease activity score in 44 joints
(DAS44), presence of rheumatoid factor (RF), sex, age,
duration of complaints and presence of erosions. All pa-
tients met the American College of Rheumatology 2010
revised criteria for RA. None had been taking disease
modifying anti-rheumatic drugs. Baseline characteris-
tics on which was matched did not significantly differ
between groups. Patients were not matched on tender
joint count, swollen joint count, C-reactive protein levels
(CRP), erythrocyte sedimentation rate (ESR) and titers of
RF. Swollen joint count and titers of RF were significantly
different between ACPA+ and ACPA− patients (Table 1).
This study was embedded in the Treatment in the Rotter-
dam Early Arthritis Cohort Study (tREACH) and approved
by the Medical Ethics Review Board of Erasmus MC
Rotterdam. Written informed consent from all patients
participating in this study was obtained.
Flow cytometry and cell culture
Monoclonal antibody stainings, transcription factor de-
tection and flow cytometry were performed as described
previously [35]. Fluorochrome labeled antibodies were pur-
chased from eBioscience (San Diego, CA), BD Biosciences,
BioLegend (San Diego, CA) and R&D systems (Minneapolis,
MN). Fixable Viability Dye and FOXP3 staining buffer sets
were purchased from eBioscience. Samples were acquired
on a LSRFortessa flow cytometer (BD Biosciences) and
analyzed using FlowJo v7.6 research software (Tree Star
Inc. Ashland, OR). Cells were gated on the lymphocyte
fraction. Th cell populations were sorted with a FACSAria
cell sorter (BD Biosciences). Purity of the obtained Th cell
populations was ≥ 98 %. Sorted Th cell populations were
stimulated with 0.3 μg/ml soluble αCD3 and 0.4 μg/ml
αCD28 (Sanquin, Amsterdam, The Netherlands) and
cultured for 4 days as described previously [31].
Quantitative real-time PCR analysis
RNA extraction and cDNA synthesis were performed as de-
scribed previously [39]. Primers were designed with Probe
Finder software and probes were used from the universal
probe library (Roche Applied Science, Indianapolis, IN).
Table 1 Baseline characteristics of ACPA+ and ACPA− treatment-naive patients with early RA
Characteristic ACPA+ patients (n = 27) ACPA− patients (n = 27) p value
DAS44 score (mean ± SD) 3.12 ± 0.82 3.14 ± 0.96 0.89
RF positive n (%) 21 (78) 16 (59) 0.07
Sex (female/male) 19/8 18/9 1.0
Age (mean ± SD, years) 48.2 ± 13.4 51.8 ± 13.8 0.31
Duration of complaints (mean ± SD, days) 159.9 ± 87.2 179.1 ± 103.5 0.29
Erosions n (%) 5 (19) 5 (19) 1.0
Tender joint count 9.93 ± 7.23 9.00 ± 7.90 0.30
Swollen joint count 6.63 ± 5.31 9.44 ± 6.67 0.02
ESR (mm/hr) 27.6 ± 22.5 26.3 ± 24.1 0.49
CRP (mg/l) 13.3 ± 30.3 11.1 ± 9.93 0.57
RF titer (IU/ml) 163 ± 327 64.3 ± 157 0.01
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analyzed using the ViiA7 sequence detection system and
software (Life Technologies, Carlsbad, CA). Hypoxanthine–
guanine phosphoribosyltransferase (HPRT) was used to
normalize gene transcription. The following primers and
probes (forward, reverse, probe no.) were used: HPRT
(5’- tgaccttgatttattttgcatacc-3’, 5’-cgagcaagacgttcagtcc-3’, 73),
IL-17A (5’-tgggaagacctcattggtgt-3’, 5’-ggatttcgtgggattgt
gat-3’, 8), IFNγ (5’-ggcattttgaagaattggaaag-3’, 5’-tttggatgctct
ggtcatctt-3’, 21), RORC (5’-cagcgctccaacatcttct-3’, 5’- cca
catctcccacatggact-3’, 69), and TBX21 (5’-tgtggtccaagttta
atcagca-3’, 5’-tgacaggaatgggaacatcc-3’, 9).
Statistical analysis
Differences between experimental groups were tested with
Wilcoxon matched-pairs signed-ranks test using Prism
software v5.04 (GraphPad Software Inc. La Jolla, CA),
unless otherwise indicated. P-values <0.05 were considered
significant.
Results
Elevated proportions of CCR6+ and CXCR3+ Th cell
subpopulations in ACPA+ patients with early RA
In a previous study we found that the proportion of CD4+
CD45RO+ (memory) T cells in PBMC of treatment-naive
early RA patients was higher than that in healthy controls
[31]. Therefore, we first checked for differences in the total
CD4+ T cell or the memory CD4+ T cell populations be-
tween the 27 matched ACPA+ and ACPA− subjects. Flow
cytometry showed similar proportions of both populations
(Fig. 1a and b).
Memory CD4+ T cell populations can be characterized
by differential expression of the chemokine receptors
CCR4, CCR6, CCR10 and CXCR3 and the surface re-
ceptor CD161 [32–34, 36]. Receptor expression analysis
revealed significantly higher proportions of CCR6 and
CXCR3 expressing memory CD4+ T cells in ACPA+ patients
compared to ACPA− patients. No significant differenceswere found for Th cells expressing CCR4, CCR10 or
CD161 (Fig. 1c).
Elevated proportions of Th22, Th17.1 and unclassified
CCR6+ Th cells in ACPA+ patients with early RA
T cells co-express different chemokine receptors on their
surface. Specific combinations of CCR4, CCR6, CCR10
and CXCR3 are expressed by human Th cell populations.
We applied a chemokine receptor gating strategy to iden-
tify memory CD4+ T cells with a Th1, Th2, Th17, Th22 or
a Th17.1 profile. Within the CD4+CD45RO+CD25− T cell
population, cells positive for CCR6 expression were gated.
Within this CCR6+ population, Th17 cells were gated as
CXCR3−CCR4+CCR10− and Th22 cells as CXCR3−CCR4+
CCR10+ [33–35]. Th17.1 cells were gated as CXCR3+
CCR4−. Using this gating strategy (Fig. 2A), an unclassified
subpopulation was identified, that was double-positive
(DP) for the expression of CCR4 and CXCR3. Recently we
validated the gating strategy for Th17 and Th22 cells of
patients with RA [35]. To validate the gating strategy for
the other CCR6+ subpopulations we sorted Th1, Th17,
Th17.1 and CCR4/CXCR3 DP CCR6+ Th cells from pa-
tients with RA and analyzed their Th17 and Th1 profile
by the transcription levels of IL-17A, IFN-γ, RORC and
TBX21. These analyses confirmed the expression profile of
Th1, Th17 and Th17.1 as reported previously [36–38]. The
CCR4/CXCR3 CCR6+ DP were IL-17A low and RORC+
with intermediate IFN-γ and TBX21 levels (Fig. 2b). This
gating strategy was applied to PBMCs of ACPA+ and
ACPA− early RA patients. Proportions of the CCR6+ Th
cell subpopulations Th22, Th17.1 and CCR4/CXCR3
DP Th cells were significantly higher in ACPA+ than in
ACPA− patients. No statistical significant (p = 0.10) dif-
ference was reached for the distribution of Th17 cells
between ACPA+ and ACPA− patients (Fig. 2c).
To investigate whether the observed increases in Th22,
Th17.1 and CCR4/CXCR3 DP memory Th cell popula-
tions in ACPA+ were due to the overall increase in CCR6+
Fig. 1 Proportions of chemokine receptor expressing memory Th cells differ between ACPA+ and ACPA− RA patients. a Fraction of CD4+ T cell
population within the total lymphocyte population of 27 ACPA+ and 27 ACPA− patients with RA. b Fraction of memory CD4+ T cell population
within the total CD4+ T cell population of 27 ACPA+ and 27 ACPA− patients with RA. c Chemokine receptor and CD161 expression on peripheral
blood memory (CD45RO+) CD4+CD25− T cells from matched ACPA+ and ACPA− patients with RA, measured by flow cytometry. For statistical
analysis Wilcoxon matched-pairs signed-ranks test was performed (* = p < 0.05).
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were taking place, the CCR6+ Th cell populations were
expressed as proportion of total CCR6+ Th cells. Interest-
ingly, the proportions of all CCR6+ subpopulations were
comparable between ACPA+ and ACPA− patients, except
the proportion of CCR4/CXCR3 DP Th cells, that was sig-
nificantly higher in ACPA+ patients than ACPA− patients
(Fig. 2d).
These findings show that, in ACPA+ patients, proportions
of Th22, Th17.1 and CCR4/CXCR3 DP subpopulations
were significantly larger than in ACPA− patients. These
increases are mainly attributed to the observed increase
in the proportion of total CCR6+ Th cells.
Th1 and Th2 proportions are similar in ACPA+ and ACPA−
patients with RA, but the CCR4/CXCR3 DP CCR6− Th cell
subpopulation is elevated in ACPA+ patients
Similar as described above, CCR6− Th cells were gated
within the CD4+CD45RO+CD25− T cell population. Cells
with a Th1 and Th2 profile were gated as CXCR3+CCR4−and CXCR3−CCR4+ respectively [32]. CCR4/CXCR3 DP
cells were identified in the CCR6− Th cell fraction (Fig. 3a).
The combination of FOXP3 and high CD25 expression by
memory CD4+ T cells was used to identify T regulatory
(Treg) cells (Fig. 3b). Proportions of Th1 and Th2 cells
did not differ between the groups. In contrast, the CCR4/
CXCR3 DP CCR6- Th cell subpopulation was higher in
ACPA+ patients than in ACPA− patients (Fig. 3c). More-
over, we found a trend for larger Treg proportions in
ACPA+ patients than in ACPA− patients (p = 0.06).
Disease duration correlates with CCR6+ Th cell
proportions in ACPA−, but not ACPA+ patients
ACPA+ and ACPA− patients with RA have a similar clin-
ical presentation in the very early phase of disease [40],
but ACPA+ RA is associated with a more severe disease
course and erosions [8–13, 41]. Therefore, we investigated
whether the differing CCR6+ Th cell, CCR6− Th cell and
Treg proportions between ACPA+ and ACPA− patients
were associated with patient-reported disease duration.
C
C
R
4
CXCR3
C
ou
nt
s
CCR10
Th17/
Th22
Th17.1
Th17 Th22
CCR6+:
Th17
0
2
4
6
8
Th17.1
0
2
4
6
8 *
Th22
0.0
0.5
1.0
1.5 *
CCR4+CXCR3+
0
1
2
3
4 *
ACPA+
ACPA-
P
er
ce
nt
ag
e  
of
C
D
4+
C
D
45
R
O
+
T
ce
lls
P
er
ce
nt
a g
e
of
C
D
4+
C
D
45
R
O
+
T
ce
lls
A
C
CCR4+/
CXCR3+
0
10
20
30
40
0
2
4
6
8
0
5
10
15
20
25
0
5
10
15
20
25
Th17
Th17.1
Th22
CCR4+CXCR3+
P
er
ce
nt
ag
e
of
tC
D
4+
C
D
45
R
O
+
C
C
R
6+
T
ce
lls
P
er
ce
nt
ag
e
of
C
D
4+
C
D
45
R
O
+
C
C
R
6+
T
ce
lls
D            
*
IL-17A
0.0
0.1
0.2
0.3
0.4
E
xp
re
ss
io
n 
re
la
tiv
e
 to
 H
P
R
T
IFNγ
0.0
0.2
0.4
0.6
RORC
0.0
0.5
1.0
1.5
TBX21
0.0
0.2
0.4
0.6
Th
1
Th
17
.1
CC
R4
+ CX
CR
3
+
Th
17 Th
1
Th
17
.1
CC
R4
+ CX
CR
3
+
Th
17
B
E
xp
re
ss
io
n 
re
la
tiv
e 
to
 H
P
R
T
Fig. 2 Memory CCR6+CD4+ T cell subpopulations are increased in ACPA+ patients compared to matched ACPA− patients. a Gating strategy for the
identification of peripheral blood Th17, Th17.1, Th22 and CCR4/CXCR3 DP cell subpopulations. CCR6+ cells were gated on CD4+CD45RO+CD25− T cells.
b Real-time PCR expression analysis for IL-17, IFNγ, RORC and TBX21 in sorted Th1, Th17, Th17.1 and CCR4/CXCR3 DP CCR6+ Th cells obtained
from patients with RA (8–10 patients per population). Prior to RNA isolation cells were stimulated with antiCD3/CD28 and cultured for 3 days.
c-d Proportions of the indicated CD4+ T cell subpopulations within the total memory CD4+ T cell population (c) and memory CCR6+CD4+ T cell
population (d) of 27 ACPA+ and 27 ACPA− patients with RA. For statistical analysis Wilcoxon matched-pairs signed-ranks test was performed (* = p< 0.05).
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proportions in ACPA+ patients, whereas it was signifi-
cantly inversely correlated with CCR6+ Th cell propor-
tions in ACPA− patients (Fig. 4). Additionally, disease
duration was significantly positively correlated with CCR6−
Th cell proportions in ACPA−, but not in ACPA+ patients
(Table 2). In contrast, neither in ACPA+ nor in ACPA− pa-
tients disease duration was associated with Treg proportion.
Further analysis of the CCR6+ Th cell compartment in
ACPA− patients showed that Th17 cells and CCR4/CXCR3
DP CCR6+ Th cells had a significant inverse correlation
with the disease duration. Within the CCR6− Th cell sub-
populations, no significant correlations were found
(Table 2). In addition, we found a small but significant in-
verse correlation between the disease duration with the
DAS in all patients together (R2 = −0.07, p < 0.05), but
not in ACPA+ patients only (R2 = −0.13, p = 0.06) and
ACPA− patients only (R2 = −0.04, p = 0.31).
These data show that CCR6+ Th cell subpopulations
are inversely correlated with disease duration in ACPA−
patients but not in ACPA+ patients.Discussion
In the present study we found that ACPA+ patients have
a higher proportion of peripheral CCR6+ Th cells than
ACPA− patients. Chemokine receptor expression analysis
revealed an increase in Th22, Th17.1 and CCR4/CXCR3
DP CCR6+ Th cells. These increases are mainly attributed
to the observed increase in the proportion of total CCR6+
Th cells. In addition, ACPA+ patients had higher propor-
tions of CCR4/CXCR3 DP CCR6− Th cells than ACPA−
patients, but did not differ in Th1 and Th2 proportions.
We also found increases in Th17 and Treg proportions
in ACPA+ patients, but these differences did not reach
statistical significance. Furthermore, in ACPA+ patients
the proportion of CCR6+ Th cells was not correlated to
disease duration, whereas in ACPA− patients proportions
of CCR6+ Th cells were negatively correlated with increas-
ing disease duration.
Our findings that the distribution of Th cell populations
is dependent on ACPA status is in line with previous stud-
ies linking ACPA+ with the CD4+ T cell component: (i)
There is a strong association between ACPA positivity and
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are mainly of the IgG subtype, which are normally synthe-
sized after T cell-mediated immunoglobulin loci class
switching; (iii) citrullinated peptide specific CD4+ T cells
are present in ACPA+ patients [23–26]. Furthermore,
PTPN22 gene polymorphisms may be involved in the for-
mation of citrullinated peptide-specific CD4+ T cells and
therefore be a risk factor for ACPA+ RA [42].
The identification of increased CCR6+ Th populations
in ACPA+ RA suggest that these cells are implicated in
the more severe disease course of patients with ACPA+ RA.
In this context, we recently identified a potential pathogenic
role for CCR6+ Th cells obtained from treatment naive pa-
tients with early RA. This included the role of CCR6+ Th
cells as potent inducers of a pro-inflammatory loop, driven
by autocrine IL-17A production and resulting in the in-
duction of IL-1β, IL-6, IL-8, PGE2 and MMPs by synovial
fibroblasts [31, 35]. This may suggest that CCR6+ Th cells
are involved in the amplification of inflammatory reac-
tions resulting in the more severe disease course ob-
served in ACPA+ RA.Given this pathogenic role of CCR6+ Th cells, it is of
particular interest that we found no correlation between
the proportion of CCR6+ Th cells and disease duration
in ACPA+ patients, while in ACPA− patients proportions
of CCR6+ Th cells were negatively correlated with increas-
ing disease duration. However, the time of onset of disease
is self-reported, and therefore an estimation. Additionally,
it is possible that the worse disease course in ACPA+
patients might lead to earlier recognition of disease onset
by ACPA+ patients than by ACPA− patients, skewing the
estimated time of onset [8–10]. Nevertheless, these data
might suggest that CCR6+ Th cells are involved in the
maintenance of inflammation in ACPA+ RA and may
underlie the differences in treatment outcome between
ACPA+ and ACPA− RA.
In a previous study it was found that IL-17A responses
by CD4+ T cells of ACPA+ patients with RA were induced
after culture with citrullinated peptides. This was not the
case for PBMCs from healthy controls. In addition, the
level of IL-17A production correlated strongly with the
level of proliferation in response to citrullinated peptides
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therefore CCR6+ Th cells as well, might be particularly
important in responses to citrullinated protein. Interest-
ingly, it has been suggested that a SNP in the CCR6 gene,
which is associated with RA, is more strongly linked to
ACPA+ RA than ACPA− RA [43–45]. Future research
should clarify whether CCR6+ Th cells have T cell recep-
tors specific for citrullinated peptides. Alternatively, it
would be interesting to compare CCL20 levels in synovial
fluid of ACPA+ and ACPA− patients, since CCL20 is the
only known ligand for CCR6 [46, 47]. Higher CCL20
levels in synovial fluid of ACPA+ patients could also ac-
count for higher CCR6+ Th cell numbers.
The CCR6+ Th population is heterogeneous, and based
on differential chemokine receptor expression various sub-
populations can be identified. The roles and contribution
of these CCR6+ Th populations in the severity of ACPA+
RA are unclear. Recently we found that Th22 cells were
not required for Th17/IL-17 mediated synovial inflamma-
tion [35]. On the other hand, Th22 cells were shown to be
associated with erosive disease and serum IL-22 levels
correlate with serum ACPA titers [48, 49]. MoreoverTable 2 Correlation of Th cell populations (% memory Th cells)
with disease duration
ACPA+ patients ACPA− patients
Population R2 P value R2 P value
CCR6+ total <0.01 0.94 −0.35 <0.01
Th17.1 0.02 0.50 −0.13 0.09
Th22 −0.04 0.37 −0.10 0.14
Th17 <0.01 0.91 −0.27 0.01
CCR4/CXCR3 DP CCR6+ <0.01 0.69 −0.36 <0.01
Treg <0.01 0.76 0.04 0.31
CCR6− total <−0.01 0.82 0.37 <0.01
Th1 0.09 0.14 <0.01 0.79
Th2 <−0.01 0.99 0.03 0.43
CCR4/CXCR3 DP CCR6− 0.02 0.51 −0.11 0.13IL-22 was able to promote osteoclastogenesis by indu-
cing RANKL in synovial fibroblasts [49].
The ontogeny of the Th17.1 CCR6+ Th cell subpopula-
tion is unclear. Th17.1 cells might be derived from Th17
cells, as culturing of human Th17 cells in the presence of
IL-12 up-regulates Th1 characteristics like TBX21 and
IFNγ and down-regulates Th17 characteristics like RORC
and IL-17, leading to a Th17.1-like phenotype [50–52]. On
the other hand, Th17.1 cells may also originate directly
from human naive T cells. Upon interaction with Candida
albicans primed monocytes, naive T cells develop into
cells with Th17.1 characteristics [53]. Recently, particular
Th17.1 cells were found to have a pathogenic signature,
specifically those that expressed the transporter protein
multi-drug resistance type 1 (MDR1), and thereby became
unresponsive to glucocorticoids [37]. The pathogenic sig-
nature and drug-resistance suggest the clinical importance
of Th17.1 cells in RA. The origin and development of the
CCR4/CXCR3 CCR6+ and CCR6− Th subpopulations are
also ill-defined, and these populations might resemble
intermediate or transitional Th cells. Research to factors
that foster the development of these cells is lacking, but
one possibility is that the micro-environment, such as
concentrations of the cytokines IL-12, IL-23 and IL-6
that are important in Th1 and Th17 differentiation, plays
a role. More research is needed to investigate the on-
togeny, stability, characteristics and functions of these
subpopulations.
Surprisingly, we found higher Treg proportions in
ACPA+ patients, although the difference did not reach
statistical significance (p = 0.06). Tregs normally play an
immune suppressive role. It might be that these increased
Tregs are induced as a feedback mechanism to control the
increased proportions of CCR6+ Th cells. However, Tregs
are able to convert to Th17 cells [54, 55]. Especially these
converted cells are key to the development of auto-
immune arthritis [56]. Future research should point out
whether the Tregs in (ACPA+) RA patients are functional
and could convert to Th17 cells.
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In this study we have found that Th cell distributions
are associated with ACPA status. In particular CCR6+ Th
cell proportions were higher in ACPA+ RA in comparison
to ACPA− RA. Moreover, CCR6+ Th cells are inversely
correlated with disease duration in ACPA− patients but
not in ACPA+ patients. These findings point toward a
pathogenic role for CCR6+ Th cells in the more severe
disease course of patients with ACPA+ RA and imply a
role for CCR6+ Th cells in the differences observed in
the treatment outcome of patients with ACPA+ and
ACPA− RA.
Abbreviations
ACPA: anti-citrullinated protein antibodies; CCR: C-C chemokine receptor;
CD: cluster of differentiation; CXCR3: CXC chemokine receptor 3; DAS44: disease
activity score, 44 joints evaluated; DP: double-positive; FOXP3: forkhead box P3;
HLA: human leukocyte antigen; IFNγ: interferon gamma, IgG, immunoglobulin
G; IL: interleukin; MDR: multi-drug resistance type 1; MHC: major
histocompatibility complex; MMP: matrix metalloproteinase; PBMCs: peripheral
blood mononuclear cells; PGE2: prostaglandin E2; PTPN22: Protein tyrosine
phosphatase, non-receptor type 22; RA: Rheumatoid arthritis; RANKL: receptor
activator of nuclear factor kappa-B ligand; RF: Rheumatoid factor; SD: Standard
deviation; SE: shared epitope; Th: T helper; TNFα: tumor necrosis factor alpha;
Treg: regulatory T cell.
Competing interests
The authors declare that they have no competing interests.
Author’s contributions
SP carried out flowcytometry, participated in the design of the study,
analyzed the data, performed the statistical analysis, evaluated the results,
and drafted the manuscript. JH carried out flowcytometry, participated in the
design of the study, analyzed the data, evaluated the results, and drafted the
manuscript. ND carried out flowcytometry, evaluated the results and revised
the manuscript. HV carried out flowcytometry, analyzed the data, performed
the statistical analysis, evaluated the results and revised the manuscript. MH
conceived of the study and revised the manuscript. PJ participated in the
design of the study, evaluated the results, helped drafting the manuscript
and conceived of the study. EL participated in the design of the study,
evaluated the results, drafted the manuscript and conceived of the study. All
authors read and approved the final manuscript.
Acknowledgements
We thank B. Bartol, H. Bouallouch-Charif and Patrick S. Asmawidjaja for
technical assistance with flow cytometry based purification of T cell
populations.
Author details
1Departments of Rheumatology and Immunology, Erasmus MC, University
Medical Center, Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The
Netherlands. 2Department of Pulmonary Medicine, Erasmus MC, University
Medical Center, Rotterdam, The Netherlands. 3Department of Rheumatology,
Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Received: 2 March 2015 Accepted: 25 September 2015
References
1. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for
all? Nat Rev Immunol. 2010;10:605–11.
2. Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition
to clinical synovitis. Nat Rev Rheumatol. 2012;8:573–86.
3. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms,
diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–64.
4. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the
present and the future. Nat Rev Rheumatol. 2011;7:391–8.5. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB,
van Venrooij WJ. Citrulline is an essential constituent of antigenic
determinants recognized by rheumatoid arthritis-specific autoantibodies.
J Clin Invest. 1998;101:273–81.
6. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der
Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the
symptoms of rheumatoid arthritis: a study of serial measurements in blood
donors. Arthritis Rheum. 2004;50:380–6.
7. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC,
Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict
progression to rheumatoid arthritis in patients with undifferentiated arthritis:
a prospective cohort study. Arthritis Rheum. 2004;50:709–15.
8. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al.
Radiological outcome in rheumatoid arthritis is predicted by presence of
antibodies against cyclic citrullinated peptide before and at disease onset,
and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65:453–8.
9. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al.
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP)
during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts
worse disease activity and greater radiological progression. Ann Rheum Dis.
2005;64:1744–9.
10. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al.
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid
arthritis: diagnostic value, associations with radiological progression rate,
and extra-articular manifestations. Ann Rheum Dis. 2004;63:1587–93.
11. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P,
et al. High anti-cyclic citrullinated peptide levels and an algorithm of four
variables predict radiographic progression in patients with rheumatoid arthritis:
results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67:212–7.
12. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW.
Antibodies to citrullinated proteins and differences in clinical progression of
rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949–958.
13. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al.
Induction of osteoclastogenesis and bone loss by human autoantibodies
against citrullinated vimentin. J Clin Invest. 2012;122:1791–802.
14. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, et al.
Efficacy of methotrexate treatment in patients with probable rheumatoid
arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.
2007;56:1424–32.
15. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T,
et al. Positivity for anti-cyclic citrullinated peptide is associated with a better
response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’
registry. Ann Rheum Dis. 2012;71:1815–9.
16. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al.
Additive effect of anti-citrullinated protein antibodies and rheumatoid factor
on bone erosions in patients with RA. Ann Rheum Dis. 2014. doi:10.1136/
annrheumdis-2014-205428.
17. Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al.
Relapse rates in patients with rheumatoid arthritis in stable remission
tapering or stopping antirheumatic therapy: interim results from the
prospective randomised controlled RETRO study. Ann Rheum Dis. 2015.
doi:10.1136/annrheumdis-2014-206439.
18. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge:
the conversion of arginine to citrulline allows for a high-affinity peptide
interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC
class II molecule. J Immunol. 2003;171:538–41.
19. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The
PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated
peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Arthritis Res Ther. 2007;9:R56.
20. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity
to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol.
2008;26:651–75.
21. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M,
de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies
only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope
alleles. Ann Rheum Dis. 2006;65:366–71.
22. van Heemst J, van der Woude D, Huizinga TW, Toes RE. HLA and
rheumatoid arthritis: how do they connect? Ann Med. 2014;46:304–10.
23. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA,
Ioan-Facsinay A, Drijfhout JW, van Tol MJ, et al. Isotype distribution of
Paulissen et al. Arthritis Research & Therapy  (2015) 17:344 Page 9 of 9anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and
rheumatoid arthritis reflects an ongoing immune response. Arthritis
Rheum. 2006;54:3799–808.
24. Van Steendam K, De Ceuleneer M, Tilleman K, Elewaut D, De Keyser F,
Deforce D. Quantification of IFNgamma- and IL17-producing cells after
stimulation with citrullinated proteins in healthy subjects and RA patients.
Rheumatol Int. 2013;33:2661–4.
25. Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG,
Drijfhout JW, et al. Identification of citrullinated vimentin peptides as T cell
epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis
Rheum. 2010;62:117–25.
26. von Delwig A, Locke J, Robinson JH, Ng WF. Response of Th17 cells to a
citrullinated arthritogenic aggrecan peptide in patients with rheumatoid
arthritis. Arthritis Rheum. 2010;62:143–9.
27. Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of
rheumatic disease. Curr Opin Rheumatol. 2014;26:204–10.
28. Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10:S1.
29. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis.
Nat Rev Immunol. 2007;7:429–42.
30. Paulissen SM, van Hamburg JP, Davelaar N, Asmawidjaja PS, Hazes JM,
Lubberts E. Synovial fibroblasts directly induce Th17 pathogenicity via the
cyclooxygenase/prostaglandin E2 pathway, independent of IL-23. J
Immunol. 2013;191:1364–72.
31. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM,
et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid
arthritis are potent inducers of matrix metalloproteinases and
proinflammatory cytokines upon synovial fibroblast interaction, including
autocrine interleukin-17A production. Arthritis Rheum. 2011;63:73–83.
32. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M,
Lanzavecchia A, et al. Surface phenotype and antigenic specificity of
human interleukin 17-producing T helper memory cells. Nat Immunol.
2007;8:639–46.
33. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of
interleukin 22 but not interleukin 17 by a subset of human skin-homing
memory T cells. Nat Immunol. 2009;10:857–63.
34. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human
helper T cell population that has abundant production of interleukin 22 and
is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10:864–71.
35. van Hamburg JP, Corneth OB, Paulissen SM, Davelaar N, Asmawidjaja PS,
Mus AM, et al. IL-17/Th17 mediated synovial inflammation is IL-22
independent. Ann Rheum Dis. 2013;72:1700–7.
36. Maggi L, Santarlasci V, Capone M, Rossi MC, Querci V, Mazzoni A, et al.
Distinctive features of classic and nonclassic (Th17 derived) human Th1
cells. Eur J Immunol. 2012;42:3180–8.
37. Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, et al.
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and
are refractory to glucocorticoids. J Exp Med. 2014;211:89–104.
38. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper
cells-origins, features and possible roles in rheumatic disease. Nat Rev
Rheumatol. 2009;5:325–31.
39. van Hamburg JP, Mus AM, de Bruijn MJ, de Vogel L, Boon L, Cornelissen F,
et al. GATA-3 protects against severe joint inflammation and bone erosion
and reduces differentiation of Th17 cells during experimental arthritis.
Arthritis Rheum. 2009;60:750–9.
40. Cader MZ, Filer AD, Buckley CD, Raza K. The relationship between the
presence of anti-cyclic citrullinated peptide antibodies and clinical
phenotype in very early rheumatoid arthritis. BMC Musculoskelet Disord.
2010;11:187.
41. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test
predicts the disease course during 3 years in early rheumatoid arthritis (the
Swedish TIRA project). Ann Rheum Dis. 2004;63:1085–9.
42. Salmond RJ, Brownlie RJ, Morrison VL, Zamoyska R. The tyrosine phosphatase
PTPN22 discriminates weak self peptides from strong agonist TCR signals. Nat
Immunol. 2014;15:875–83.
43. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al.
Genome-wide association study meta-analysis identifies seven new
rheumatoid arthritis risk loci. Nat Genet. 2010;42:508–14.
44. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, et al. A regulatory
variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat
Genet. 2010;42:515–9.45. Jiang L, Yin J, Ye L, Yang J, Hemani G, Liu AJ, et al. Novel risk loci for
rheumatoid arthritis in Han Chinese and congruence with risk variants in
Europeans. Arthritis Rheumatol. 2014;66:1121–32.
46. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its
receptor CCR6. Cytokine Growth Factor Rev. 2003;14:409–26.
47. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N,
et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed
joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med.
2007;204:2803–12.
48. Leipe J, Schramm MA, Grunke M, Baeuerle M, Dechant C, Nigg AP, et al.
Interleukin 22 serum levels are associated with radiographic progression in
rheumatoid arthritis. Ann Rheum Dis. 2011;70:1453–7.
49. Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22
promotes osteoclastogenesis in rheumatoid arthritis through induction of
RANKL in human synovial fibroblasts. Arthritis Rheum. 2012;64:1015–23.
50. Nistala K, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, et al. Th17
plasticity in human autoimmune arthritis is driven by the inflammatory
environment. Proc Natl Acad Sci U S A. 2010;107:14751–6.
51. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al.
Phenotypic and functional features of human Th17 cells. J Exp Med.
2007;204:1849–61.
52. Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B,
Desai B, et al. Human Th17 cells comprise heterogeneous subsets including
IFN-gamma-producing cells with distinct properties from the Th1 lineage. J
Immunol. 2010;185:679–87.
53. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M,
et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10
and are regulated by IL-1beta. Nature. 2012;484:514–8.
54. Cooles FA, Isaacs JD, Anderson AE. Treg cells in rheumatoid arthritis: an
update. Curr Rheumatol Rep. 2013;15:352.
55. Wang T, Sun X, Zhao J, Zhang J, Zhu H, Li C, et al. Regulatory T cells in
rheumatoid arthritis showed increased plasticity toward Th17 but retained
suppressive function in peripheral blood. Ann Rheum Dis. 2015;74:1293–301.
56. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al.
Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune
arthritis. Nat Med. 2014;20:62–8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
